Key Takeaway: Molecular Partners and Orano Med have initiated a Phase 1/2a trial for DLL3-targeting Radio-DARPin MP0712, with the first patients dosed. The trial is being conducted at five sites in the US, and initial data is anticipated in the coming months, while comprehensive efficacy data is expected by 2027.
Price reaction · baseline $3.93 (2026-07-01 close) · hit pre-market · 1 other MOLN headline(s) in the window, move may be shared
day 0 close
+1.3%
Market Sentiment Analysis
POSITIVE FACTORS
First patients have been dosed in the trial.
The study is actively recruiting at five sites in the US.
Initial data is expected soon, indicating progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.3%
average across 2 past catalysts
Lead asset
ensovibep
Phase 2 · Covid19
Full Press Release Details
Five sites recruiting in US study of DLL3-targeting 212 Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 ZURICH-SCHLIEREN, Switzerland
Frequently Asked Questions
What is the DLL3-targeting Radio-DARPin MP0712?
DLL3-targeting Radio-DARPin MP0712 is a therapeutic agent being tested in a clinical trial.
Where is the Phase 1/2a trial being conducted?
The trial is being conducted at five sites across the United States.
When is initial data expected from the trial?
Initial data from the trial is anticipated within the coming months.
When will comprehensive efficacy data be available?
Comprehensive efficacy data is expected to be available in 2027.